drugset / Trial / NCT04990609

EUS-RFA PANCARDINAL-1 Trial

NCT04990609 ↗

NaSingle-groupOpen-labelTreatment

Summary

The objectives of this study are to determine the feasibility, tolerability, and treatment effect of endoscopic ultrasound (EUS) radiofrequency ablation (RFA) plus standard-of-care neoadjuvant chemotherapy (NAC) in the treatment of pancreatic ductal adenocarcinoma (PDAC). Endoscopic ultrasound (EUS) radiofrequency ablation (RFA) and neoadjuvant chemotherapy (NAC) will be performed before tumor resection surgery, with the goal of shrinking a tumor or stopping the spread of cancer so that surgery might be less invasive and more effective.

Timeline

Start
2021-08-13
Primary completion
2026-12-01
Completion
2028-05-30

Drugs

EvaluationDrugModalityDoseRoute
Background Cisplatin Other / unclassified — —
Background Gemcitabine Small molecule — —
Background Nab-paclitaxel Small molecule — —